| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |